)
Autolus Therapeutics (AUTL) investor relations material
Autolus Therapeutics TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Product launch and market performance
Launched first product, obe-cel, a CD19 CAR-T therapy for relapsed/refractory adult acute leukemia, achieving $75 million in first-year revenue and rapid market leadership.
Secured approvals in the U.K. and Europe, including a positive NICE review, enabling routine commissioning and broad market access.
Expanded to 70 U.S. centers with plans to reach 80+ by year-end, targeting $120–$135 million in net revenue and positive gross margin in year two.
Achieved over 90% manufacturing success rate, with robust, semi-automated processes and no capacity limitations.
Ongoing optimization of manufacturing and supply chain to improve gross margins over the next 24–36 months.
Clinical data and real-world outcomes
Real-world data from the ROCCA Consortium shows zero high-grade CRS, 3% high-grade ICANS, and over 90% response rate, outperforming competitors.
FELIX study and commercial experience confirm strong safety and efficacy, supporting rapid adoption and market leadership.
Pediatric pivotal study in phase II, showing high response rates and good safety profile, even in high-risk frontline patients.
Ongoing pivotal studies in lupus nephritis and exploratory study in progressive MS, leveraging differentiated mechanism of action.
Expansion into new indications
Targeting pediatric ALL, lupus nephritis, and progressive MS, with pivotal and exploratory studies underway.
Early-stage collaboration on BCMA/CD19 CAR-T for light chain amyloidosis, with initial data expected by year-end.
Lupus nephritis pivotal study (LUMINOUS) enrolling 30 patients for full approval, with plans for expanded indications.
Progressive MS study (BOBCAT) enrolling patients with high unmet need; initial data expected end of this year or early next.
Next Autolus Therapeutics earnings date
Next Autolus Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage